Results 101 to 110 of about 1,416 (129)
[XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)]. [PDF]
Rev NeurolFernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. +23 moreeuropepmc +1 more source[XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)]. [PDF]
Rev NeurolFernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. +23 moreeuropepmc +1 more sourceDiffusivity anisotropy signature of slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis. [PDF]
J Neurol Neurosurg PsychiatryCalvi A, Vivó Pascual F, Solana E, Lopez-Soley E, Kanber B, Alba-Arbalat S, Sepulveda M, Martínez-Hernández E, Cabrera-Maqueda JM, Fonseca E, Medrano-Martorell S, Saiz A, Blanco Y, Villoslada P, Prados Carrasco F, Martinez-Heras E, Llufriu S. +16 moreeuropepmc +1 more sourceOzanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis. [PDF]
Int J Mol SciCosta-Frossard L, Brieva L, García-Estévez DA, Martín-Martínez JM, Álvarez-Bravo G, Blasco-Quílez MR, Meca-Lallana JE, Calles-Hernández MC, Ramo Tello C, Muñoz-Fernández C, Barbero DE, López-Muñoz P, Prieto González JM, Candeliere-Merlicco A, Carmona O, Riancho J, Sola-Valls N, Carcelén-Gadea M, Borrega L, Gascón-Giménez F, Vilanova D, Pérez X, Villar LM. +22 moreeuropepmc +1 more sourceAccess, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America. [PDF]
Ther Adv Neurol DisordSilva BA, Santajuliana F, Casas M, Lázaro L, Pita C, Cohen L, Rinaldi G, Alonso R, Míguez J, D'Alessandro S. +9 moreeuropepmc +1 more sourceCombining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis. [PDF]
Int J Mol SciMonreal E, Fernández-Velasco JI, Sainz de la Maza S, Espiño M, Villarrubia N, Roldán-Santiago E, Aladro Y, Cuello JP, Ayuso-Peralta L, Rodero-Romero A, Chico-García JL, Rodríguez-Jorge F, Quiroga-Varela A, Rodríguez-Martín E, Pilo de la Fuente B, Martín-Ávila G, Martínez-Ginés ML, García-Domínguez JM, Rubio L, Llufriu S, Comabella M, Montalban X, Álvarez-Bravo G, Veiga-González JL, Masjuan J, Costa-Frossard L, Villar LM. +26 moreeuropepmc +1 more source
